Molecular docking studies of kirenol a traditional Chinese medicinal compound against rheumatoid arthritis cytokine drug targets (TNF-α, IL-1 and IL-6).

Jing Wu#, Yuan Qu#, Jia-xin Deng, Wan-yi Liang, Zhen-lan Jiang, Rong Lai, Qing-hong Yu*

Department of Rheumatology and Clinical Immunology, ZhuJiang Hospital of Southern Medical University, Guangzhou 510282, PR China

#These authors contributed equally to this work

Abstract

Rheumatoid Arthritis (RA) an autoimmune multifactorial disease impairing the quality of life of the diseased is a challenging prospect in terms of treatment. The disease has been treated from ancient times and from their wisdom, we have taken one traditional Chinese medicinal compound named kirenol. The compound is from herbal extract of Herba Siegesbeckiae and in this study we are exploring its inhibiting potential of cytokine target i.e. TNF-α, IL-1 and IL-6 using Auto Dock tool. In our study we have used Auto Dock 4.2 an Insilico tool to check the effect of the kirenol on three important cytokine target i.e. TNF-α, IL-1 and IL-6. The molecular docking approach using AutoDock 4.2 tool with default parameters was used to calculate the binding energies. All the three cytokines showed spontaneous binding with kirenol, varying from a ΔG range of -6.75 to -2.68 Kcal/mole. The results generated showed IL-6 to be the best target for kirenol. Both, its binding energy and number of interactions is higher when compared to that of other two.

Keywords: Rheumatoid arthritis, TNF-α, IL-1, IL-6, Kirenol, Molecular docking.

Introduction

Rheumatoid Arthritis (RA) is an autoimmune disease resulting in chronic inflammation disorder that affects many tissues and organs in almost 1% of the adult population [1]. RA is characterized by the chronic inflammation of synovial membrane in affected joints, ultimately leading to dysfunction of joint [2]. The impaired quality of life, joint deformity, morbidity and mortality are the features of RA [3,4]. The etiology of RA is unknown, however progress have been made in development of new therapeutics [5].

Since 1998 new biological drugs for RA have been introduced and approved for treatment [6], these drugs are known as Disease Modifying Anti-Rheumatic Drugs (DMARDs), which have role in curbing the underlying process of the disease and they have become the mainstay of the treatment of RA [7]. In our institute (ZhuJiang hospital) for the treatment of RA a new compound called kirenol is being used to a great effectiveness. Kirenol, a Traditional Chinese Medicine (TCM) is an extract of Herba Siegesbeckiae botanical name Siegesbeckia pubescens Mak a traditionally used herb found abundantly in China and practiced for the treatment of arthritis, hypertension, malaria, neurasthenia and snakebite [8].

As the compound possess anti-inflammatory properties and is a known TCM against RA, so we used it for molecular docking analysis against the cytokine target involved in RA. The main three known targets of RA disease are TNF-α, IL-1 and IL-6 [9-14] were considered for the study.

Material and Methods

Protein preparation

The crystallographic structures of proteins TNF-α, IL-1 and IL-6 were retrieved from protein database website (www.pdb.org). TNF-α crystallographic structure bearing PDB ID: 2AZ5 was selected for the study [15] the partial crystallographic structure of TNF-α covered the protein structure from amino acid 10-157. IL1 crystallographic structure bearing PDB ID: 2ILA from position 117-271 [16]. The third structure of Il-6 (PDB ID: 1ALU) covered from 28 -212 of the protein structure [17]. All the three structures were trimmed according to the needs of the study using Discovery Studio 3.5 Visualizer [18]. The energy minimization of the trimmed protein was cried out by SPDB Viewer.

Ligand structure

For kirenol compound, the coordinates were taken from NCBI PubChem compound database (www.pubchem.ncbi.nlm.nih.gov/) bearing Chem ID:
The structure was in molfile format and was changed to PDB format using Discovery Studio 3.5 Visualizer.

**Molecular docking**

The docking of kirenol into TNF-α, IL-1 and IL-6 crystallographic structure was performed using AUTODOCK 4.2 [19]. The AUTODOCKTOOLS [20] were used for preparing the protein for docking, the polar hydrogens, partial charges and Gastegier charges were added using these tools. The flexible torsion of the ligand was assigned same for all three proteins; the AutoGrid tool was used to implement the auto grid file, different for each protein. The grid parameters set for each run are in Table 1. The AutoDock was finally used for blind docking of kirenol into the crystallographic structure of TNF-α, IL-1 and IL-6.

**Table 1. The Grid parameters followed for blind docking of kirenol into TNF-α, IL-1 and IL-6.**

<table>
<thead>
<tr>
<th>Target Protein</th>
<th>Grid Size Å (x, y, z)</th>
<th>Coordinates (x, y, z)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>118, 106, 94</td>
<td>-25.6, 67.1, 42.6</td>
</tr>
<tr>
<td>IL-1</td>
<td>126, 90, 90</td>
<td>0.8, -0.6, -1.1</td>
</tr>
<tr>
<td>IL-6</td>
<td>122, 110, 100</td>
<td>2.6, -19.9, 8.8</td>
</tr>
</tbody>
</table>

**Visualization**

The docking log file of each run was used to generate top three binding poses of each protein, based on the binding energy of kirenol. The saved poses were visualized using Discovery Studio 3.5 Visualizer.

**Results**

The crystallographic structure of TNF-α constituted: four subunits, water and the ligand. The structure was trimmed to a single subunit as shown in Figure 1a. The IL-1 crystallographic structure was used as such for the blind docking (Figure 1b). The IL-6 structure was trimmed and the modifications are shown in Figure 1c. The Psi-Phi distribution of the trimmed protein structures before and after energy minimizations are depicted in Figure 2, showing the structures after energy minimization within the ramachandran limit.

**Table 2. Top three binding energies of each TNF-α, IL-1 and IL-6 with kirenol, the results are generated by AutoDock4.2.**

<table>
<thead>
<tr>
<th>Target Protein</th>
<th>Rank</th>
<th>ΔG (Kcal/mole)</th>
<th>No. of Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>1</td>
<td>-6.75</td>
<td>One</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-4.56</td>
<td>One</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>-4.17</td>
<td>Two</td>
</tr>
<tr>
<td>IL-1</td>
<td>1</td>
<td>-4.9</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-3.89</td>
<td>Three</td>
</tr>
</tbody>
</table>
Molecular docking studies of kirenol a traditional Chinese medicinal compound against rheumatoid arthritis cytokine drug targets (TNF-α, IL-1 and IL-6)

<table>
<thead>
<tr>
<th>Target Protein</th>
<th>ΔG (Kcal/mol)</th>
<th>Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>-4.17</td>
<td>Kirenol: O23-TNF-α: IL136: O (2.6 Å°)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TNF-α:LEU26:N - Kirenol:O24(2.7 Å°)</td>
</tr>
<tr>
<td>IL-1</td>
<td>-3.89</td>
<td>Kirenol: O24 - IL1:LEU92: O (2.8 Å°)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-1:GLN38:HE22 - Kirenol:O24(2.1 Å°)</td>
</tr>
<tr>
<td>IL-6</td>
<td>-6.72</td>
<td>Kirenol: O19 - IL-6:ASN63: O (2.1 Å°)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-6:LEU64:N - Kirenol:O19(2.8 Å°)</td>
</tr>
</tbody>
</table>

The second most spontaneous interaction of kirenol-IL1 protein is the most stable, with the number of hydrogen bonds being three. Its binding pocket comprises of GLN25, LEU26, ASP45, ASN46, GLU135 and ILE136. The O atom at the 18th position of kirenol is forming the hydrogen bonds with ASN63 and LEU64 with a distance of 2.7 Å°.

Discussion

RA is a disease with unknown pathophysiology leading to joint destruction and ultimately disability. The disease can be targeted via various important biological pathways involved, the important drug able target molecules of these pathways can be targeted and in our study we are looking into the TCM compound kirenol, a traditionally used RA drug and are exploring it cytokine based targets TNF-α, IL-1 and IL-6 by in silico approaches. Natural origin compounds have tremendous potential in blocking immunomodulators [21], our study also looks into the prospective activity of resveratrol on RA by targeting immunomodulators. Kirenol has been long reported to have an effect on RA [22], however the mechanistic mechanism of action was yet to be elucidated. In summary, the results of this study provide a comprehensive assessment of immunosuppressive pathways by which Kirenol can induce a potent protective effect against RA.

Acknowledgement

The authors would like to take an opportunity to thank the management of ZhuJiang hospital for providing the funding and computational support to carry forward this work.

References


20. Sanner MF, Duncan BS, Carrillo CJ, Olson AJ. Integrating computation and visualization for biomolecular analysis: an example using python and AVS. Pac Symp Biocomput 1999; 401-412.


*Correspondence to:*
Qing-hong Yu
Department of Rheumatology and Clinical Immunology
ZhuJiang hospital of Southern Medical University
PR China